Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

SoCal’s Cytori Pink Slips 50 Percent of Workforce in Restructuring

Cytori Therapeutics is terminating half of its employees a little more than one month after the company’s late-stage cell therapy to treat scleroderma failed to achieve statistical significance for both the primary and secondary trial endpoints.

Read More »

Death puts Cellectis cell therapy tests on hold

French cell therapy specialist Cellectis, which is developing a gene-modified cancer treatment, was forced to suspend testing following a patient death.

Read More »

Bad blood over Obamacare fight lingers as Congress returns

As the U.S. Congress returns from summer vacation, for the first time in years gutting Obamacare will not be the main order of business on the healthcare agenda.

Read More »

Novartis names new CEO for 2018

Novartis CEO Joe Jimenez will step down on Feb. 1, 2018, and hand over the top leadership role of the Swiss company to drug development chief Vas Narasimhan.

Read More »

FDA approves Pfizer’s leukemia drug

The U.S. Food and Drug Administration approved Pfizer Inc.’s drug Mylotarg for certain patients with acute myeloid leukemia (AML), re-clearing a drug that had been pulled off the market in 2010.

Read More »

Cycle for Survival Invests $34 Million in Rare Cancer Research in 2017

Cycle for Survival, the movement to beat rare cancers, announced funding plans for the $34 million raised in 2017 by its extraordinary community. 100 percent of this record-breaking total goes to rare cancer research and clinical trials to improve how cancer is diagnosed and treated.

Read More »

Cancer Biotech ImMAGE Shutters Operations

ImMAGE Biotherapeutics announced the company is shutting its doors and discontinuing operations.

Read More »

Johnson & Johnson Dissolves $700 Million R&D Deal With MacroGenics

Janssen Biotech is terminating the collaboration and license agreement with MacroGenics relating to duvortuxizumab, a CD19 x CD3 DART molecule.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom